title: Association between p53 Pro72Arg polymorphism and prostate cancer risk: a meta-analysis.
abstract: The tumor suppressor gene p53 appears to be important in the development of many human cancers, such as prostate cancer. The association of p53 codon72 polymorphism with prostate cancer has been widely reported; however, the results are inconsistent. To derive a more precise estimation of this relationship, we performed an updated meta-analysis from 10 case-control studies. We conducted a search in the PubMed database without a language limitation, covering all papers published until July 2010. Risk ratios (RR) with 95% confidence intervals (CIs) were used to assess the strength of the association. Ten studies including 1,196 cases and 1,704 controls were selected. Overall, no significant differences of total prostate cancer risk and p53 codon polymorphism was found (Pro/Pro vs Arg/Arg, RR = 1.12, 95%CI=0.74-1.70, P heterogeneity = 0.016, I (2) = 55.8%; Pro/Pro+Pro/Arg vs Arg/Arg, RR = 1.05, 95%CI=1.00-1.11, P heterogeneity = 0.077, I (2) = 51.1%). In the stratified analysis by ethnicity, the same results were found. However, in the control subgroup, there was a modest decreased association between prostate cancer risk and population-based control subjects under the recessive genetic model (RR = 0.31, 95%CI=0.10-0.91, P heterogeneity = 0.110, I (2) =60.8%). This meta-analysis suggested that p53 codon Pro72Arg polymorphism could be weakly associated with prostate cancer risk.
authors.affiliation: Department of Urology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China;
authors.forename: Lifeng
authors.initials: L
authors.lastname: Zhang
authors.forename: Ning
authors.initials: N
authors.lastname: Shao
authors.forename: Qianqian
authors.initials: Q
authors.lastname: Yu
authors.forename: Lixin
authors.initials: L
authors.lastname: Hua
authors.forename: Yuanyuan
authors.initials: Y
authors.lastname: Mi
authors.forename: Ninghan
authors.initials: N
authors.lastname: Feng
keywords: meta-analysis; p53; polymorphism; prostate cancer; risk
references.citation: Cell. 1997 Feb 7;88(3):323-31
references.pmid: 9039259
references.citation: CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49
references.pmid: 19474385
references.citation: J Cell Biochem Suppl. 1994;19:217-23
references.pmid: 7823594
references.citation: Clin Trials. 2005;2(3):209-17
references.pmid: 16279144
references.citation: Oncogene. 2004 Apr 22;23(19):3328-37
references.pmid: 15077186
references.citation: J Urol. 2009 Apr;181(4):1907-12
references.pmid: 19237173
references.citation: Clin Cancer Res. 2007 Sep 1;13(17):5056-62
references.pmid: 17785557
references.citation: BMC Urol. 2005 Nov 24;5:15
references.pmid: 16307686
references.citation: Prostate. 2010 Dec 1;70(16):1739-45
references.pmid: 20593380
references.citation: Prostate. 2001 Dec 1;49(4):263-6
references.pmid: 11746272
references.citation: J Natl Cancer Inst. 1959 Apr;22(4):719-48
references.pmid: 13655060
references.citation: Control Clin Trials. 1986 Sep;7(3):177-88
references.pmid: 3802833
references.citation: Arch Med Res. 2009 Oct;40(7):625-34
references.pmid: 20082880
references.citation: Nat Genet. 2000 May;25(1):47-54
references.pmid: 10802655
references.citation: Nat Genet. 2003 Mar;33(3):357-65
references.pmid: 12567188
references.citation: J Biomed Sci. 2003 Jul-Aug;10(4):430-5
references.pmid: 12824702
references.citation: Breast Cancer Res Treat. 2011 Jan;125(1):201-5
references.pmid: 20496166
references.citation: Cancer Epidemiol Biomarkers Prev. 2010 Jul;19(7):1840-7
references.pmid: 20615891
references.citation: Ann Epidemiol. 2002 Apr;12(3):182-96
references.pmid: 11897176
references.citation: Gene. 1992 Aug 15;117(2):271-5
references.pmid: 1639275
references.citation: Urology. 2010 Sep;76(3):765.e1-7
references.pmid: 20630574
references.citation: Breast Cancer Res Treat. 2010 Apr;120(3):705-14
references.pmid: 19657731
references.citation: Eur J Cancer Prev. 2010 Jul;19(4):299-307
references.pmid: 20389250
references.citation: Jpn J Cancer Res. 1995 Aug;86(8):730-6
references.pmid: 7559095
references.citation: Nature. 1992 Jul 2;358(6381):15-6
references.pmid: 1614522
references.citation: Nat Rev Cancer. 2004 Nov;4(11):850-60
references.pmid: 15516958
references.citation: BMJ. 1997 Sep 13;315(7109):629-34
references.pmid: 9310563
references.citation: Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6632-8
references.pmid: 18006764
references.citation: J Cell Sci. 2001 Dec;114(Pt 23):4139-40
references.pmid: 11739646
references.citation: Urol Int. 2004;73(1):41-6
references.pmid: 15263792
references.citation: Asian J Androl. 2006 May;8(3):349-55
references.pmid: 16625286
references.citation: Oncogene. 1997 Aug 18;15(8):887-98
references.pmid: 9285684
references.citation: Nat Rev Cancer. 2009 Feb;9(2):95-107
references.pmid: 19165225
references.citation: Int J Cancer. 2009 Dec 15;125(12):2903-11
references.pmid: 19623649
references.citation: Cancer Epidemiol Biomarkers Prev. 2004 Dec;13(12):2217-24
references.pmid: 15598783
references.citation: Cancer Epidemiol Biomarkers Prev. 2004 Jan;13(1):11-22
references.pmid: 14744727
references.citation: Science. 2004 Feb 13;303(5660):1010-4
references.pmid: 14963330
references.citation: Nat Cell Biol. 2004 May;6(5):443-50
references.pmid: 15077116
references.citation: BMJ. 2003 Sep 6;327(7414):557-60
references.pmid: 12958120